The gastrointestinal stent market is expanding as clinicians increasingly relieve digestive tract obstructions without open surgery. Valued at USD 586.23 million in the base year 2025, the gastrointestinal stent market is projected to reach USD 618.54 million in 2026 and USD 958.81 million by 2034, growing at a CAGR of 5.62% during the forecast period 2026–2034. Key players include Boston Scientific Corporation, Medtronic plc, Olympus Corporation, Cook Medical LLC, Merit Medical Systems, Inc., and Becton, Dickinson and Company.

Understanding the Gastrointestinal Stent Market

GI stents are medical devices that treat obstructions in the esophagus, stomach, intestines, and bile ducts by keeping the passage from narrowing or blocking, particularly in cases of cancer and stricture formation. They are commonly used in hospitals and ambulatory surgery centers. Demand is supported by greater awareness of early detection, improvements in endoscopic techniques, and physician preference for treatments with shorter recovery periods.

The sector operates within the regulatory structure for medical devices, which aims to ensure safety, efficacy, and procedural success. Advances in stent technology, expanding healthcare infrastructure, and the availability of skilled endoscopists are also supporting growth.

Core Growth Drivers

Rising gastrointestinal cancer incidence is a primary driver. According to the American Cancer Society (2025), GI cancer cases are projected to reach 9.06 million globally by 2050, an increase of 85% compared with 2022. Stents are widely used to relieve blockages caused by esophageal, colorectal, and pancreatic cancer.

The shift toward minimally invasive GI procedures is equally influential. As cited by the National Library of Medicine, adoption of minimally invasive surgery among 1,142 colorectal cancer resections rose from 51.2% in 2012 to 93.6% in 2024. Because stents treat obstructions without resorting to surgery, growing preference for minimally invasive GI procedures lifts endoscopy use in clinics and supports reduced risks and shorter hospital stays.

Medical practitioners are increasingly adopting stent-based procedures to reduce surgical risks. Artificial intelligence is adding precision as well, since image-guided placement and predictive, real-time decision support can optimize stent selection.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/gastrointestinal-stent-market

Product and Material Segments

The biliary stent segment dominated in 2025 with approximately 38.65% share, driven by rising biliary obstructions linked to pancreatic cancer and gallstones. Pancreatic stents are expected to post the highest CAGR of approximately 13.80%, supported by increasing pancreatitis and pancreatic cancer cases. SEER reports show 66,440 newly diagnosed pancreatic cancer cases in the US in 2024, equal to 3.3% of all new cancer diagnoses, while wider use of endoscopic retrograde cholangiopancreatography (ERCP) supports segment expansion.

By material, metal stents held the largest share at approximately 42.25% in 2025 owing to durability and longer patency. Technologies such as self-expanding metal stents (SEMS) and degradable designs have improved outcomes. The biodegradable stent segment is projected to grow at the fastest CAGR because these devices break down naturally after serving their purpose. In December 2025, University of Iowa Health Care performed the first US clinical procedure with the FDA-approved ARCHIMEDES biodegradable pancreatic device.

Healthcare providers are also emphasizing advanced designs that ensure patency and minimize complications, which is expected to boost biliary segment growth.

Application and End-Use Trends in the Gastrointestinal Stent Market

Biliary disease led applications in 2025 with approximately 36.90% share, reflecting gallstones and bile duct obstructions, especially in elderly patients. Colorectal cancer is projected to grow at the fastest CAGR, supported by rising malignancy burden and screening programs. Hospitals dominated end use in 2025 owing to high procedure volumes and advanced endoscopic infrastructure, while ambulatory surgical centers are expected to grow fastest as outpatient and same-day procedures gain preference.

High device costs, coverage limitations, and cost-sharing burdens constrain adoption in budget-conscious regions. Gastrointestinal Stent-related complications, including migration, occlusion, perforation, and infection, can require repeat procedures and raise costs.

GI stenting demands costly equipment, endoscopy systems, and specialized medical knowledge, which creates cost challenges in budget-conscious regions and makes some physicians cautious because of safety concerns and medical outcomes.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market